B
Bart Barlogie
Researcher at University of Arkansas for Medical Sciences
Publications - 8
Citations - 524
Bart Barlogie is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Multiple myeloma & Thalidomide. The author has an hindex of 7, co-authored 8 publications receiving 513 citations.
Papers
More filters
Journal ArticleDOI
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Maurizio Zangari,Bart Barlogie,Elias Anaissie,Fariba Saghafifar,Paul Eddlemon,Joth Jacobson,Choon Kee Lee,Raymond Thertulien,Giampaolo Talamo,Teri Thomas,Frits van Rhee,Athanasios Fassas,Louis M. Fink,Guido Tricot +13 more
TL;DR: The experience, although not based on a randomized study, suggests that the excess frequency of thrombosis in patients treated with chemotherapy and thalidomide can be safely reduced by the prophylactic use of LMWH.
Journal ArticleDOI
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,David Irwin,Paul G. Richardson,Ruben Niesvizky,Raymond Alexanian,Steven A. Limentani,Melissa Alsina,Dixie-Lee Esseltine,Kenneth C. Anderson +11 more
TL;DR: Notable survival, response, and time‐to‐progression data suggest that a bortezomib starting dose of 1·3’mg/m2 is preferred, and if bortzomib dose reduction is required, the 1·0 mg/ m2 dose still offers patients a substantial survival benefit.
Journal ArticleDOI
Bradycardia during therapy for multiple myeloma with thalidomide
Ibrahim E. Fahdi,Venkat Gaddam,Jorge F. Saucedo,Channarayapatna V Kishan,Keyur Vyas,Matthew G. Deneke,Hani Razek,Brett Thorn,Joe K. Bissett,Elias Anaisse,Bart Barlogie,Jawahar L. Mehta +11 more
TL;DR: Reducing the thalidomide dose appeared to alleviate symptoms in most patients and reduce the heart rate was found to be the most effective method to treat symptom-related bradycardia.
Journal ArticleDOI
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
TL;DR: Preliminary results corroborate the role for thalidomide and CC-5013 in relapsed/refractory and newly diagnosed multiple myeloma based on the UAMS phase II study as well as several other studies of these agents outside of UAMS.